glp-1 agonist. receptor agonists show promise in treating substance use disorders Hype Or Hope? Latest Research

Bernard Bihari was a New York doctor treating heroin addicts during the AIDS epidemic when he noticed something weird: patients taking tiny doses of naltrexonejust 3mg instead of the usual 50mghad much better immune function 1

Empagliflozin and cardiovascular and kidney outcomes across KDIGO risk categories: post hoc analysis of a randomized, double-blind, placebo-controlled, multinational trial

Sun exposure is also important here as it stimulates the production of cholesterol sulfate

Overtime, CMS has refined the definition through regulation, rulemaking comments, and guidance (Figure 2)

We conducted a safety evaluation of the candidate compounds, followed by an assessment of their therapeutic effects in APP/PS1 transgenic mice